RxDoctor Payments Data

Lindsey Criss

Family · Amarillo, TXNPI 1225656952

Payments from drug & device makers

$15,195in general payments, 2019–2025

Across 756 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • AbbVie$2K
  • Boston Scientific$1K
  • EMD Serono, Inc.$1K
  • Novartis$845
  • Biogen$830
  • plus $6K from 37 others

What the payments were for

  • Travel & lodging$3,18521%
  • Food & beverage$11,91178%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,195 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$64,433
Medicare patients
351
Services billed
3,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab26$227,463
NourianzIstradefylline49$144,535
VumerityDiroximel Fumarate12$103,756
VyeptiEptinezumab-Jjmr14$75,504
RytaryCarbidopa/Levodopa112$72,484
NuplazidPimavanserin Tartrate11$53,846
BriviactBrivaracetam33$48,225
TrintellixVortioxetine Hydrobromide77$43,901
Teriflunomide11$38,561
QuliptaAtogepant24$34,392
UbrelvyUbrogepant23$33,592
Aimovig AutoinjectorErenumab-Aooe29$29,920
Nurtec OdtRimegepant Sulfate24$29,626
AuvelityDextromethorphan Hbr/Bupropion22$26,037
Emgality PenGalcanezumab-Gnlm28$24,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kyowa Kirin, Inc.Nourianz$339$144,53549 claims
BiogenVumerity$830$103,75612 claims
Lundbeck LLCVyepti$406$75,50414 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil$175$73,862141 claims
AbbVieQulipta, Ubrelvy$2,397$67,98447 claims
UCB, Inc.Briviact, Neupro$383$59,60846 claims
Acadia Pharmaceuticals IncNuplazid$29$53,84611 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$190$43,90177 claims
PfizerNurtec Odt$475$29,62624 claims
Axsome Therapeutics, Inc.Auvelity$41$26,03722 claims
SK Life Science, Inc.Xcopri$312$24,29020 claims
Eisai Inc.Fycompa$314$13,03211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →